^
Association details:
| Biomarker: | ERBB3 expression + CD73 expression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Erbitux (cetuximab) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Gene expression markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance)
Excerpt:
HER3 and CD73 expression levels were identified as potential predictive markers of benefit from cetuximab.
DOI:
10.1158/1078-0432.CCR-14-2313
